Sai’s Science Gets a Bigger Lab Coat—Bidar Facility Expansion Now in Motion

Sai Life Sciences Ltd. (SAIE.NS) today commenced the second phase of expansion of its production block at its showcase API and intermediates manufacturing facility in Bidar, Karnataka, as a reflection of its commitment to building global Contract Research, Development, and Manufacturing Organization (CRDMO) capacity.

 

The expansion forms part of the company's long-term plan to meet growing demands from international pharma innovators and biotechnology firms. The Bidar plant, already approved by USFDA and PMDA, is a significant contributor in supplying early-phase to commercial-scale APIs and intermediates to regulated markets like the US, Europe, and Japan.

 

The new manufacturing facility will include advanced containment systems, automatic hydrogenation units, and multi-purpose production trains, that can turnaround faster and safely. This will increase installed reactor capacity significantly, improve supply chain responsiveness, and support Sai Life's revenue 15–20% CAGR target over the next 3–5 years.

 

The announcement follows investor interest at high levels, with Sai Life shares increasing 5% intraday on June 20 following a huge block deal of 10% equity turnover, which has been linked to the sale by TPG Asia of part of its stake. 

 

Expansion Highlights:

Sources: Sai Life Sciences, Business Standard, CNBC-TV18